Partnership Will Provide Pharmaceutical Grade Cannabinoid Active Ingredients to the Largest Pharmaceutical and Consumer Goods Names in the Industry
/EIN News/ — BUFFALO, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced filing of a U.S. Drug Master File (DMF) to the US Food & Drug Administration (FDA) for cannabidiol (CBD) API from GVB Biopharma, a 22nd Century Group Company. The submission (DMF 037727) demonstrates 22nd Century Group’s absolute commitment to supplying high quality pharmaceutical grade API to the pharmaceutical industry and OTC markets.
Said James A. Mish, chief executive officer of 22nd Century, “GVB Biopharma is widely recognized for the quality and consistency of its Cannabinoid extracts and ingredients. We are now leveraging these capabilities with our DMF filing to meet the increasing regulatory demands of the supplements markets, and in parallel it expands our reach to the pharmaceutical and OTC markets, where consistently regulated high quality ingredients are a requirement. Our compliance infrastructure will ensure that our customers consistently receive API that meets the appropriate quality standards.”
Additionally, 22nd Century and GVB Biopharma have entered into an agreement with Cannabinoid API…
Original Author Link click here to read complete story..
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
- Source: https://mmpconnect.com/22nd-century-group-xxii-announces-filing-of-u-s-dmf-drug-master-file-for-cbd-api-new-global-sales-marketing-and-distribution-agreement-with-tra/?utm_source=rss&utm_medium=rss&utm_campaign=22nd-century-group-xxii-announces-filing-of-u-s-dmf-drug-master-file-for-cbd-api-new-global-sales-marketing-and-distribution-agreement-with-tra